In a patient taking both quetiapine (Seroquel) and oxcarbazepine who develops myoclonus, which medication should be discontinued first?

Discontinue Quetiapine (Seroquel) First

In a patient on both quetiapine and oxcarbazepine who develops myoclonus, quetiapine should be discontinued first, as both medications are independently associated with drug-induced myoclonus, but quetiapine carries the additional risk of serotonin syndrome which can present with myoclonus and requires immediate cessation.

Rationale for This Recommendation

Both Medications Can Cause Myoclonus

The most recent systematic review on drug-induced myoclonus (2025) provides Level A evidence that both oxcarbazepine and quetiapine are established causes of myoclonus 1. This means either drug could be the culprit, requiring a strategic approach to discontinuation.

Quetiapine Poses Greater Immediate Risk

Quetiapine-associated myoclonus may signal serotonin syndrome, a potentially life-threatening condition requiring immediate drug cessation 2, 3. When quetiapine is combined with other serotonergic medications (even if not currently prescribed, consider recent medication history), myoclonus can be an early warning sign of serotonin toxicity. The FDA label for quetiapine does not specifically list myoclonus as a common adverse effect, but case reports document dose-related myoclonic jerks that resolve with dose reduction or discontinuation 4.

Oxcarbazepine Has More Predictable Patterns

Oxcarbazepine-induced myoclonus typically occurs in specific contexts:

• Paradoxical worsening in idiopathic generalized epilepsy (particularly juvenile myoclonic epilepsy), where it exacerbates pre-existing myoclonic seizures 5, 6
• Epileptic negative myoclonus in symptomatic focal epilepsies 7
• These patterns are more predictable and less immediately life-threatening than serotonin syndrome

The FDA label for oxcarbazepine does not list myoclonus as a primary adverse effect, but multiple case reports document seizure aggravation in susceptible patients 8.

Clinical Decision Algorithm

Step 1: Assess for Serotonin Syndrome Features

Look for accompanying symptoms beyond myoclonus:

• Autonomic instability: tachycardia (HR >100 bpm), diaphoresis, hyperthermia
• Neuromuscular excitation: hyperreflexia, clonus (especially ocular or inducible), tremor, muscle rigidity
• Altered mental status: agitation, confusion, restlessness

If ANY of these are present: This is serotonin syndrome until proven otherwise—discontinue quetiapine immediately and provide supportive care (benzodiazepines, IV fluids, consider cyproheptadine) 2, 3.

Step 2: Determine Epilepsy Type (If Applicable)

• If the patient has idiopathic generalized epilepsy (especially juvenile myoclonic epilepsy): Oxcarbazepine is likely worsening their underlying seizure disorder—discontinue oxcarbazepine 5, 6
• If the patient has focal epilepsy or no epilepsy: Proceed to Step 3

Step 3: Default Strategy When Unclear

Discontinue quetiapine first because:

• Quetiapine can be stopped abruptly without significant withdrawal seizure risk (unlike benzodiazepines or barbiturates)
• Oxcarbazepine requires gradual taper to avoid withdrawal seizures, especially in patients taking it for seizure control
• The potential for serotonin syndrome makes quetiapine the higher-risk medication to continue

Step 4: Taper Oxcarbazepine If Needed

If myoclonus persists after quetiapine discontinuation, taper oxcarbazepine gradually over 2-4 weeks to minimize withdrawal seizure risk. Abrupt oxcarbazepine discontinuation can precipitate seizures even in patients without epilepsy.

Important Caveats

Monitor for Withdrawal Effects

• Quetiapine withdrawal: Watch for rebound insomnia, nausea, or return of psychiatric symptoms (not typically dangerous)
• Oxcarbazepine withdrawal: Risk of seizures requires gradual taper; consider bridging with another antiepileptic if needed for seizure control

Dose-Response Relationship

Both medications show dose-dependent myoclonus 4. If discontinuation is not immediately feasible due to underlying psychiatric or neurological conditions, dose reduction of quetiapine should be attempted first as a temporizing measure while arranging alternative therapy.

Hyponatremia Consideration

Oxcarbazepine commonly causes hyponatremia (2.5% develop sodium <125 mmol/L), which can independently cause neurological symptoms including myoclonus 8. Check serum sodium levels—if significantly low, this may be contributing to symptoms and requires correction regardless of which medication is discontinued.

Time Course Matters

• Quetiapine-induced myoclonus typically appears with dose escalation and resolves within days of discontinuation 4
• Oxcarbazepine-induced seizure worsening usually occurs within weeks of initiation in susceptible patients 7, 5

The clinical context of when myoclonus developed relative to medication initiation or dose changes can provide additional guidance, but when in doubt, prioritize quetiapine discontinuation due to serotonin syndrome risk.